Novartis AG ADR (NVS)vsPrecigen Inc (PGEN)
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
PGEN
Precigen Inc
$6.85
+2.54%
HEALTHCARE · Cap: $2.46B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 66040% more annual revenue ($56.69B vs $85.72M). NVS leads profitability with a 22.5% profit margin vs -184.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
PGEN
Hold40
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Intrinsic value data unavailable for PGEN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Strong operational efficiency at 41.2%
Revenue surging 6323.0% year-over-year
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% earnings growth
Weak financial health signals
Trading at 57.1x book value
ROE of -1145.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : PGEN
The strongest argument for PGEN centers on Operating Margin, Revenue Growth. Revenue growth of 6323.0% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : PGEN
The primary concerns for PGEN are EPS Growth, Piotroski F-Score, Price/Book. Debt-to-equity of 2.26 is elevated, increasing financial risk.
Key Dynamics to Monitor
NVS profiles as a value stock while PGEN is a hypergrowth play — different risk/reward profiles.
PGEN carries more volatility with a beta of 1.02 — expect wider price swings.
PGEN is growing revenue faster at 6323.0% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 40/100), backed by strong 22.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Precigen Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Precigen, Inc. discovers and develops the next generation of cell and gene therapies in the United States. The company is headquartered in Germantown, Maryland.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?